UNSPSC 51121518: Moricizine

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C22H25N3O4S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 2GT1D0TMX1, chemically known as phenothiazine-2-carbamic acid, 10-(3-morpholinopropionyl)-, ethyl ester but more generally known as moracizine, which bears U.S. National Institutes of Health Compound Identifier 34633. The European Medicines Agency schedules Moracizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09062MIG.

UNSPSC 51121518 Moricizine is a Commodity code representing a single pharmaceutical product — an antiarrhythmic medication — that state and local governments procure primarily through emergency medical services and pharmacy benefit programs. State and local buyers under this code include municipal fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work involves sourcing branded or generic moricizine tablets or injections to stock emergency medical equipment, support pharmacy formularies, or fulfill direct-to-manufacturer prescription agreements. Vendors must meet FDA compliance, maintain product shelf life minimums, provide Safety Data Sheets compliant with OSHA standards, and often submit pricing through wholesaler chargeback systems or negotiate net pricing models.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026 (due April 8, 2026) for Advanced Life Support Medications including four cardiac-emergency drugs for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year term renewable for two additional one-year periods; the solicitation carried a 5 percent bid discount for Small Local Business Enterprises. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to explore vendor capacity for direct-to-manufacturer prescription programs serving state employee health plans, signaling the state's intent to bypass traditional pharmacy benefit managers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, effective July 1, 2026, requiring vendors to maintain relationships with three authorized wholesalers and comply with the Drug Supply Chain Security Act and current Good Manufacturing Practices. None of the three opportunities explicitly named moricizine as a line item, indicating the code captures niche activity within broader emergency-medicine and pharmacy-benefit solicitations.